Literature DB >> 31123908

Novel miRNAs as potential biomarkers in stage II colon cancer: microarray analysis.

Cigdem Gungormez1,2, Hatice Gumushan Aktas3, Nihat Dilsiz4, Ersin Borazan5.   

Abstract

The aim of this study was to determine oncogenic and tumor-suppressing miRNA profiles associated with the development and progression of cancer using tumor tissues from patients with colorectal cancer (stage II) that did not show nodal spread or advanced metastasis to identify potential biomarkers. A microarray system (GeneChip miRNA 4.0 Array chip, Affymetrix) was used to determine the microRNA profiles of five patients with stage II colon cancer based on normal and colon tumor tissues. Of 32 identified miRNAs, an increase in three microRNAs (hsa-miR-4745-5p, hsa-miR-6126, and hsa-miR-1469) was observed in tumor tissues relative to that in control tissues. Additionally, this study demonstrated for the first time that the expression of the 8 miRNAs (hsa-miR-378i, hsa-miR-378a-3p, hsa-miR-378c, hsa-miR-378d, hsa-miR-378e, hsa-miR-378f, hsa-miR-378a-5p, and hsa-miR-378g) from miR-378 members among the differentially expressed miRNAs is reduced. The target genes of these downregulated miRNAs were determined by using DIANA miRPath v3. The effect of identified genes on colon cancer stage II was determined the biological process and biological pathway using Funrich Gene Enrichment. It was revealed that these miRNAs were affected the signaling pathways which control cell proliferation, cell-cell interaction, and apoptosis in stage II colon cancer. In patients with early stage II colon cancer, miR-378 can be used as a biomarker of colorectal cancer. Thus, miR-378 can facilitate treatment with early diagnosis.

Entities:  

Keywords:  Biomarker; Oncogenic miRNA; Stage II colorectal cancer; Tumor suppressor miRNA; microRNA

Mesh:

Substances:

Year:  2019        PMID: 31123908     DOI: 10.1007/s11033-019-04868-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  16 in total

Review 1.  Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Shanthi Sabarimurugan; Madurantakam Royam Madhav; Chellan Kumarasamy; Ajay Gupta; Siddharta Baxi; Sunil Krishnan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

2.  MiR-378a-3p Acts as a Tumor Suppressor in Colorectal Cancer Stem-Like Cells and Affects the Expression of MALAT1 and NEAT1 lncRNAs.

Authors:  Giorgia Castellani; Mariachiara Buccarelli; Valentina Lulli; Ramona Ilari; Gabriele De Luca; Francesca Pedini; Alessandra Boe; Nadia Felli; Mauro Biffoni; Emanuela Pilozzi; Giovanna Marziali; Lucia Ricci-Vitiani
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

3.  The SP1-Induced Long Noncoding RNA, LINC00339, Promotes Tumorigenesis in Colorectal Cancer via the miR-378a-3p/MED19 Axis.

Authors:  Hua Ye; Wende Li; Kefeng Wu; Yi Liu; Yingnian Lv; Yuzhen Zhu; Hui Luo; Liao Cui
Journal:  Onco Targets Ther       Date:  2020-11-16       Impact factor: 4.147

4.  LINC00963 Promotes Ovarian Cancer Proliferation, Migration and EMT via the miR-378g /CHI3L1 Axis.

Authors:  Wei Liu; Yu-Jia Yang; Qiang An
Journal:  Cancer Manag Res       Date:  2020-01-21       Impact factor: 3.989

5.  MicroRNA‑378d inhibits Glut4 by targeting Rsbn1 in vitamin D deficient ovarian granulosa cells.

Authors:  Huiting Sun; Yichao Shi; Yuwei Shang; Xia Chen; Fei Xia
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

6.  Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.

Authors:  Jian Lei; Zhen-Yu He; Jun Wang; Min Hu; Ping Zhou; Chen-Lu Lian; Li Hua; San-Gang Wu; Juan Zhou
Journal:  Cancer Med       Date:  2021-03-19       Impact factor: 4.452

7.  Relationship between miR-378c and YY1 expression in patients with gastric cancer and the clinicopathological features.

Authors:  Lei Zhang; Lei Zou; Peng Sun
Journal:  Cell Mol Biol Lett       Date:  2021-04-01       Impact factor: 5.787

8.  Genome-Wide Expression Difference of MicroRNAs in Basal Cell Carcinoma.

Authors:  Hai-Peng Wei; Song Zhan; Qing-An Zhu; Zhen-Juan Chen; Xian Feng; Jun-Yuan Chen; Qi-Lin Zhang; Jingjie Zhao; Lingzhang Meng
Journal:  J Immunol Res       Date:  2021-08-04       Impact factor: 4.818

9.  Inhibition of miR-378a-3p by Inflammation Enhances IL-33 Levels: A Novel Mechanism of Alarmin Modulation in Ulcerative Colitis.

Authors:  Karen Dubois-Camacho; David Diaz-Jimenez; Marjorie De la Fuente; Rodrigo Quera; Daniela Simian; Maripaz Martínez; Glauben Landskron; Mauricio Olivares-Morales; John A Cidlowski; Xiaojiang Xu; Guangping Gao; Jun Xie; Jonás Chnaiderman; Ricardo Soto-Rifo; María-Julieta González; Andrea Calixto; Marcela A Hermoso
Journal:  Front Immunol       Date:  2019-11-20       Impact factor: 7.561

10.  miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway.

Authors:  Haibo Zou; Lan Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.